Search

Your search keyword '"Zeng,Zhi-ming"' showing total 13 results
Start Over Author "Zeng,Zhi-ming"
13 results on '"Zeng,Zhi-ming"'

1. Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

Author

Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Xu, Bin, Wu, Dong, Ji, Yuan, Chen, Ling-Li, Song, Tian-Qiang, Zhang, Wei, Zeng, Zhi-Ming, Huang, Hua-Sheng, Wang, Kui, Huang, Lan-Qing, Chen, Yong-Jun, Yang, Yu-Chen, Zhou, Le-Du, Long, Guo, Zhao, Hai-Tao, Wang, Yun-Chao, Ge, Ning-Ling, Chen, Yi, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, and Sun, Hui-Chuan

Published
2023
Full Text
View/download PDF

2. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy

Author

Wei, Yong-Guang, primary, Su, Hao, additional, Lv, Zi-li, additional, Liao, Xi-Wen, additional, Zeng, Zhi-Ming, additional, Jia, Yu-Xuan, additional, Huang, Hua-Sheng, additional, Shen, Xiao-Qiang, additional, Zhu, Guang-Zhi, additional, Han, Chuang-Ye, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2023
Full Text
View/download PDF

4. Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti–PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study

Author

Xu, Bin, primary, Dong, Sanyuan, additional, Bai, Xue-Li, additional, Song, Tian-Qiang, additional, Zhang, Bo-Heng, additional, Zhou, Le-Du, additional, Chen, Yong-Jun, additional, Zeng, Zhi-Ming, additional, Wang, Kui, additional, Zhao, Hai-Tao, additional, Lu, Na, additional, Zhang, Wei, additional, Li, Xu-Bin, additional, Zheng, Su-Su, additional, Long, Guo, additional, Yang, Yu-Chen, additional, Huang, Hua-Sheng, additional, Huang, Lan-Qing, additional, Wang, Yun-Chao, additional, Liang, Fei, additional, Zhu, Xiao-Dong, additional, Huang, Cheng, additional, Shen, Ying-Hao, additional, Zhou, Jian, additional, Zeng, Meng-Su, additional, Fan, Jia, additional, Rao, Sheng-Xiang, additional, and Sun, Hui-Chuan, additional

Published
2022
Full Text
View/download PDF

6. Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.

Author

Xu, Bin, Dong, San-Yuan, Bai, Xue-Li, Song, Tian-Qiang, Zhang, Bo-Heng, Zhou, Le-Du, Chen, Yong-Jun, Zeng, Zhi-Ming, Wang, Kui, Zhao, Hai-Tao, Lu, Na, Zhang, Wei, Li, Xu-Bin, Zheng, Su-Su, Long, Guo, Yang, Yu-Chen, Huang, Hua-Sheng, Huang, Lan-Qing, Wang, Yun-Chao, and Liang, Fei

Subjects
PROGRESSION-free survival, CONTRAST-enhanced magnetic resonance imaging, FEATURE extraction, MAGNETIC resonance imaging, NEUTROPHIL lymphocyte ratio
Abstract

Introduction: Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combination therapy in advanced HCC patients. Methods: Patients (N = 170) who received first-line combination therapy with lenvatinib plus an anti-PD-1 antibody were retrospectively enrolled from 9 Chinese centers; 124 and 46 into the training and validation cohorts, respectively. Radiomic features were extracted from pretreatment contrast-enhanced MRI. After feature selection, clinicopathologic, radiomic, and clinicopathologic-radiomic models were built using a neural network. The performance of models, incremental predictive value of radiomic features compared with clinicopathologic features and relationship between radiomic features and survivals were assessed. Results: The clinicopathologic model modestly predicted objective response with an AUC of 0.748 (95% CI: 0.656–0.840) and 0.702 (95% CI: 0.547–0.884) in the training and validation cohorts, respectively. The radiomic model predicted response with an AUC of 0.886 (95% CI: 0.815–0.957) and 0.820 (95% CI: 0.648–0.984), respectively, with good calibration and clinical utility. The incremental predictive value of radiomic features to clinicopathologic features was confirmed with a net reclassification index of 47.9% (p < 0.001) and 41.5% (p = 0.025) in the training and validation cohorts, respectively. Furthermore, radiomic features were associated with overall survival and progression-free survival both in the training and validation cohorts, but modified albumin-bilirubin grade and neutrophil-to-lymphocyte ratio were not. Conclusion: Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy

Author

Zhu, Guang-Zhi, primary, Liao, Xi-Wen, additional, Wang, Xiang-Kun, additional, Gong, Yi-Zhen, additional, Liu, Xiao-Guang, additional, Yu, Long, additional, Han, Chuang-Ye, additional, Yang, Cheng-Kun, additional, Su, Hao, additional, Huang, Ke-Tuan, additional, Yu, Ting-Dong, additional, Huang, Jian-Lu, additional, Li, Jia, additional, Zeng, Zhi-Ming, additional, Qin, Wei, additional, Liu, Zheng-Qian, additional, Zhou, Xin, additional, Liu, Jun-Qi, additional, Lu, Lei, additional, Han, Quan-Fa, additional, Shang, Li-Ming, additional, Ye, Xin-Ping, additional, and Peng, Tao, additional

Published
2020
Full Text
View/download PDF

9. Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report

Author

Ma,Fu-chao, Yu,Qian, Zeng,Zhi-ming, He,Rong-quan, Mo,Chao-hua, Zhong,Jin-cai, Ma,Jie, Feng,Zhen-Bo, Chen,Gang, and Hu,Xiao-Hua

Subjects
OncoTargets and Therapy
Abstract

Fu-Chao Ma,1 Qian Yu,1 Zhi-Ming Zeng,1 Rong-Quan He,1 Chao-Hua Mo,2 Jin-Cai Zhong,1 Jie Ma,1 Zhen-Bo Feng,2 Gang Chen,2 Xiao-Hua Hu1 1Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, 2Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China Abstract: Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase inhibitor that targets the intracellular domain of vascular endothelial growth factor receptor-2. To the best of our knowledge, this is the first case report of the successful use of apatinib for advanced ICC; this treatment has demonstrated fewer toxic effects than traditional cytotoxic chemotherapy. The progression-free survival time was 8 months. The only toxicity observed was mild hand–foot syndrome. Therefore, apatinib may be an additional option for the treatment of advanced ICC, but further prospective studies are needed to optimize the treatment. Keywords: advanced intrahepatic cholangiocarcinoma, apatinib, PFS, cholangiocarcinoma, VEGFR-2, targeted therapy

Published
2017

11. Human papillomavirus as a potential risk factor for gastric cancer: a meta-analysis of 1,917 cases

Author

Zeng,Zhi-ming, Luo,Fei-fei, Zou,Lin-xia, He,Rong-quan, Pan,Deng-hua, Chen,Xin, Xie,Ting-ting, Li,Yuan-qing, Peng,Zhi-gang, Chen,Gang, Zeng,Zhi-ming, Luo,Fei-fei, Zou,Lin-xia, He,Rong-quan, Pan,Deng-hua, Chen,Xin, Xie,Ting-ting, Li,Yuan-qing, Peng,Zhi-gang, and Chen,Gang

Abstract

Zhi-ming Zeng,1 Fei-fei Luo,2 Lin-xia Zou,3 Rong-quan He,1 Deng-hua Pan,2 Xin Chen,2 Ting-ting Xie,2 Yuan-qing Li,2 Zhi-gang Peng,1 Gang Chen2 1Department of Medical Oncology, 2Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 3Department of Children Rehabilitation Medicine, Guangxi Maternal and Child Health Hospital, Nanning, China Background: Human papillomaviruses (HPVs) are causally associated with the tumorigenesis of several classes of cancers. However, the prevalence of HPV in gastric cancer (GC) has not yet been systematically reviewed. Hence, a meta-analysis was conducted to estimate the HPV prevalence in patients with GC, and its potential etiologic significance was assessed. Methods: The pooled HPV prevalence and 95% confidence intervals (CIs) were estimated among all GC patients. Heterogeneity was described by using the I2 statistic. Sources of heterogeneity were explored by meta-regression and stratified analyses. The meta-influence was applied to evaluate the influence of a single study on the pooled estimates. Odds ratios (ORs) and 95% CIs were computed for case–control studies. For research providing clinicopathological parameters of age, sex, pathological, differentiated, and clinical stages, and HPV subtypes, the corresponding pooled ORs and 95% CIs were also calculated. Results: Thirty studies were included in the current meta-analysis, involving 1,917 patients with GC and 576 controls. The pooled HPV prevalence was 28.0% (95% CI: 23.2%, 32.7%) among all the patients with GC, and the I2 was 96.9% (P<0.001). A pooled OR of 7.388 (95% CI: 3.876, 14.082) was achieved based on 15 case–control studies (I2=56.7%, P=0.004). Moreover, the HPV prevalence was significantly higher in patients from China than in those from non-Chinese regions (31% vs 9%, I2=95.0%, P<0.001). The pooled prevalence of HPV16 was 21% in GC tissues, and the pooled prevalence of HPV18 was 7% with an OR of 3.314 (9

Published
2016

12. The study of the performance of IP switching

Author

Zeng Zhi Ming, Zhang Ling Yun, Yu Hao, and Ding Wei

Subjects
Routing protocol, Router, Virtual routing and forwarding, Computer science, business.industry, IP forwarding, IP Multimedia Subsystem, Internet traffic, Optical IP Switching, Internet traffic engineering, Loose Source Routing, Telecommunications network, IP tunnel, LAN switching, Asynchronous Transfer Mode, Reserved IP addresses, Next-generation network, The Internet, business, Computer network
Abstract

The explosive growth of Internet traffic has made IP routers the bottleneck of the Information Super Highway. In order to improve router performance, many new routing mechanisms have been proposed. Among these technologies, the most popular are Ipsilon's IP switching, Cisco's tag switching, IBM's ARIS and Toshiba's CSR. This paper concerns the first of these and is mainly interested in simulating the performance of IP switching in some circumstances; the flow algorithm is very important to the IP switching, affecting directly the performance of the IP switch. We analyse some kinds of flow classification, then simulate traffic with priority level in a static algorithm. We analyse the result and it is valuable for multimedia, especially for real time traffic.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results